Table 1: Dosing information and diagnoses for enrolled subjects.
PO = oral administration. Tube = enteric tube administration.
NG = nasogastric; G = gastric; GJ = gastrojejunal; RSV = respiratory syncytial virus
| Patient and Dosing Characteristics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subject # (based on enrollment order) | Age (yrs) | Weight (kg) | Reason for PICU admission | Influenza Testing result/Other infectious diagnosis | Route (Tube [NG, G,GJ]/PO) | Formulation | Day of Oseltamivir when PK sampling done | Dosing # | Dosagea (mg) | Food within 2 hours of oseltamivir doses? |
| Subjects administered oseltamivir orally (PO) | ||||||||||
| 3 | 6 | 19.5 | Uncompensated septic shock | Influenza A | PO | Suspension | 1 | 1 | 45 | No |
| 5 | 7 | 25 | Respiratory failureb | Influenza B | PO | Capsule | 1 | 1 | 60 | No |
| 10 | 5 | 15.2 | Status asthmaticus | Influenza A | PO | Suspension | 2 | 3 | 45 | No |
| 11 | 11 | 64.8 | Septic shock, respiratory distress | Negative/Rhinovirus | PO | Capsule | 1 | 2 | 75 | Yes |
| Subjects administered oseltamivir by enteric tube | ||||||||||
| 1 | 6 | 22 | Respiratory failure | Negative/RSV | Tube (GJ) | Suspension | 1 | 1 | 45 | No |
| 2 | 2 | 9 | Respiratory failure | Negative/RSV | Tube (NG) | Suspension | 1 | 1 | 30 | No |
| 4 | 8 | 18.9 | Septic shock, hypoxia | Influenza B | Tube (G) | Suspension | 1 | 1 | 45 | No |
| 6 | 15 | 46.7 | Septic shock, respiratory failure | Influenza B/Haemophilus influenzae, Streptococcus pneumoniae | Tube (G) | Suspension | 1 | 1 | 78c | Yes |
| 4 | 7 | |||||||||
| 7 | 0.67 | 9.7 | Respiratory failure | Influenza A/RSV | Tube (NG) | Suspension | 1 | 2 | 30 | Yes |
| 4 | 8 | |||||||||
| 8 | 13 | 32 | Respiratory failure | Influenza A | Tube (G) | Suspension | 1 | 1 | 60 | Yes |
| 4 | 7 | |||||||||
| 9 | 19 | 64.5 | Septic shock, hemorrhage, respiratory failure | Influenza B/Pseudomonas aeruginosa, Stenotrophomonas, Candida | Tube (NG) | Suspension | 4 | 7 | 78 | No |
a
Dosage recommendations (https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf):
Ages 2 weeks – 1 year: 3 mg/kg twice daily
Ages 1–12 years: <15 kg or less: 30 mg twice daily; 15.1–23 kg: 45 mg twice daily; 23.1–40 kg: 60 mg twice daily; 40.1 kg or more: 75 mg twice daily
Ages > 12 years: 75 mg twice daily
b
Defined as requiring positive pressure ventilation or intubation
c
Higher dose given due to rounding of volume of suspension